Gasdermin D mediates the pathogenesis of neonatal-onset multisystem inflammatory disease in mice by Xiao, Jianqui et al.




Gasdermin D mediates the pathogenesis of
neonatal-onset multisystem inflammatory disease
in mice
Jianqui Xiao
Washington University School of Medicine in St. Louis
Chun Wang
Washington University School of Medicine in St. Louis
Juo-Chin Yao
Washington University School of Medicine in St. Louis
Yael Alippe
Washington University School of Medicine in St. Louis
Canxin Xu
Confluence Discovery Technologies, Inc., St. Louis
See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Xiao, Jianqui; Wang, Chun; Yao, Juo-Chin; Alippe, Yael; Xu, Canxin; Kress, Dustin; Civitelli, Roberto; Abu-Amer, Yousef; Kanneganti,
Thirumala-Devi; Link, Daniel C.; and Mbalaviele, Gabriel, ,"Gasdermin D mediates the pathogenesis of neonatal-onset multisystem
inflammatory disease in mice." PLoS Biology.16,11. e3000047. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/7326
Authors
Jianqui Xiao, Chun Wang, Juo-Chin Yao, Yael Alippe, Canxin Xu, Dustin Kress, Roberto Civitelli, Yousef Abu-
Amer, Thirumala-Devi Kanneganti, Daniel C. Link, and Gabriel Mbalaviele
This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/open_access_pubs/7326
SHORT REPORTS
Gasdermin D mediates the pathogenesis of
neonatal-onset multisystem inflammatory
disease in mice
Jianqiu Xiao1☯, Chun Wang1☯, Juo-Chin YaoID2, Yael AlippeID1, Canxin Xu3,
Dustin Kress1, Roberto CivitelliID1, Yousef Abu-Amer4, Thirumala-Devi Kanneganti5,
Daniel C. Link2, Gabriel MbalavieleID1*
1 Division of Bone and Mineral Diseases, Washington University School of Medicine, St. Louis, Missouri,
United States of America, 2 Division of Oncology, Washington University School of Medicine, St. Louis,
Missouri, United States of America, 3 Confluence Discovery Technologies, Inc., St. Louis, Missouri, United
States of America, 4 Department of Orthopedic Surgery, Washington University School of Medicine and
Shriners Hospital for Children, St. Louis, Missouri, United States of America, 5 Department of Immunology,
St. Jude Children’s Research Hospital, Memphis, Tennessee, United States of America
☯ These authors contributed equally to this work.
* gmbalaviele@wustl.edu
Abstract
Mutated NLRP3 assembles a hyperactive inflammasome, which causes excessive secre-
tion of interleukin (IL)-1β and IL-18 and, ultimately, a spectrum of autoinflammatory disor-
ders known as cryopyrinopathies of which neonatal-onset multisystem inflammatory
disease (NOMID) is the most severe phenotype. NOMID mice phenocopy several features
of the human disease as they develop severe systemic inflammation driven by IL-1β and IL-
18 overproduction associated with damage to multiple organs, including spleen, skin, liver,
and skeleton. Secretion of IL-1β and IL-18 requires gasdermin D (GSDMD), which—upon
activation by the inflammasomes—translocates to the plasma membrane where it forms
pores through which these cytokines are released. However, excessive pore formation
resulting from sustained activation of GSDMD compromises membrane integrity and ulti-
mately causes a pro-inflammatory form of cell death, termed pyroptosis. In this study, we
first established a strong correlation between NLRP3 inflammasome activation and
GSDMD processing and pyroptosis in vitro. Next, we used NOMID mice to determine the
extent to which GSDMD-driven pyroptosis influences the pathogenesis of this disorder.
Remarkably, all NOMID-associated inflammatory symptoms are prevented upon ablation of
GSDMD. Thus, GSDMD-dependent actions are required for the pathogenesis of NOMID in
mice.
Author summary
The NLRP3 inflammasome plays an important role in the maturation of interleukin (IL)-
1β and IL-18. Accordingly, NLRP3 gain-of-function mutations, which cause a spectrum of
autoinflammatory disorders known as cryopyrin-associated periodic syndromes (CAPS),
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are associated with excessive IL-1β and IL-18 production. Although CAPS-associated
inflammatory symptoms are treated with IL-1-blocking agents, emerging evidence indi-
cates that some CAPS patients only partially respond to these drugs. Persistent inflamma-
tory responses have also been reported in CAPS mice deficient in IL-1β and IL-18
signaling and may be the consequences of the pro-inflammatory cell death, pyroptosis,
which is induced by gasdermin D (GSDMD), the other effector of the inflammasomes.
Consistent with this view, we found that damage to multiple organs that manifested in a
mouse model of CAPS was prevented by ablation of GSDMD.
Introduction
NLRP3, also called cryopyrin, assembles an inflammasome complex upon sensing danger sig-
nals triggered by structurally different exogenous and endogenous molecular entities [1–3].
Failure to clear the insults or restore homeostasis leads to chronic activation of this inflamma-
some, a response that underlies various inflammatory and metabolic diseases, including gout,
diabetes, and atherosclerosis [4]. Activating mutations in the NLRP3 gene also cause constitu-
tive activation of the NLRP3 inflammasome in patients with a spectrum of autoinflammatory
disorders known as cryopyrinopathies or cryopyrin-associated periodic syndromes (CAPS),
which include neonatal-onset multisystem inflammatory disease (NOMID), Muckle-Wells
syndrome (MWS), and familial cold autoinflammatory syndrome (FCAS) [5, 6]. CAPS are
monogenic disorders with some degree of genotype-phenotype correlation, with NOMID
exhibiting the most severe manifestations [5, 6]. Each of the CAPS phenotypes displays multi-
ple symptoms, including systemic inflammation, recurrent or chronic fever, and urticaria-like
rash [5, 6].
Consistent with the NLRP3 inflammasome role in interleukin (IL)-1β and IL-18 matura-
tion, cryopyrinopathies are associated with excessive production of these cytokines. Accord-
ingly, IL-1-blocking drugs are widely used in the management of these disorders. However, it
appears that some CAPS patients only partially respond to IL-1 biologics [7–9]. In addition,
skeletal lesions, the hallmark of NOMID, are refractory to IL-1 blockade [10–13]. These clini-
cal observations underscore the complexity of cryopyrinopathies by suggesting that other
actions of the inflammasomes beyond maturation of cytokines also contribute to the patho-
genesis of these disorders. Indeed, the NLRP3 inflammasome also processes gasdermin D
(GSDMD) into GSDMD-N (N-terminal domain) and GSDMD-C (C-terminal domain) [14–
16]. GSDMD-N translocates to the plasma membrane, where it binds phospholipids and
forms pores at the plasma membrane through which IL-1β and IL-18 are secreted by living
cells [17–19]. Sustained activity of the inflammasomes causes excessive maturation of GSDMD
and pore formation; this leads to membrane perforation and, ultimately, pyroptosis [17, 20–
23]. This form of cell death provokes the uncontrolled release of not only IL-1β and IL-18 but
also cytoplasmic contents, resulting in the recruitment of immune cells and propagation of
inflammation [17, 24]. Thus, pyroptosis is not a silent endpoint, but the extent to which this
pathologic process influences the pathogenesis of cryopyrinopathies is unknown.
Knockin mice harboring specific mutations found in CAPS patients were engineered in an
attempt to generate preclinical disease-relevant models for genotype-phenotype relationship
studies [25–28]. These models recapitulate some clinical features though disease manifesta-
tions are, in general, more severe in mice than in humans. Nonetheless, these seminal studies
revealed that pyroptosis may be responsible for the persistent inflammatory responses in mice
with impaired IL-1β and IL-18 signaling [8, 29]. Here, we used NOMID mice to determine the
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role that GSDMD and pyroptosis play in this disease model. NOMID mice exhibited systemic
inflammation, stunt growth, and damage to multiple organs. These anomalies were absent in
NOMID mice lacking GSDMD, which were indistinguishable from wild-type (WT) litter-
mates. These results reveal a nonredundant function of GSDMD in the onset and progression
of NOMID in mice.
Results and discussion
Maturation of GSDMD and IL-1β, and pyroptosis, occur constitutively in
NOMID cells
The NLRP3 inflammasome complex—which comprises NLRP3 itself, the adapter protein,
apoptosis-associated speck-like protein containing a CARD (ASC), and caspase-1—processes
pro-IL-1β and pro-IL-18 into IL-1β and IL-18, respectively [1]. This inflammasome also
cleaves GSDMD into GSDMD-N and GSDMD-C [14–16]. GSDMD-N forms pores at the
plasma membranes through which IL-1β and IL-18 are secreted by living cells; excessive pore
formation causes pyroptosis, a response that can be assessed in vitro by quantifying the release
of lactate dehydrogenase (LDH) [18, 19]. Consistent with the literature, GSDMD was cleaved
upon stimulation of WT mouse bone marrow–derived macrophages (BMMs) with lipopoly-
saccharide (LPS) and nigericin (Fig 1A). Two cleaved GSDMD fragments were detected;
whether the larger fragment was further processed to generate the smaller fragment is not
known. GSDMD maturation correlated with the release of not only IL-1β (Fig 1B and S1 Data)
but also LDH (Fig 1C and S1 Data), indicating that BMMs undergo NLRP3 inflammasome-
dependent pyroptosis under these experimental conditions. To reinforce this conclusion,
GSDMD processing, cytokine production, and pyroptosis were determined using cells isolated
from mice lacking GSDMD or components of either the NLRP3 canonical inflammasome
(e.g., NLRP3 or caspase-1) or noncanonical inflammasome (e.g., caspase-11). Maturation of
IL-1β and GSDMD was impaired in BMMs lacking any component of the classical NLRP3
inflammasome but was unaffected in Casp11 null cells (Fig 1A–1C), as expected. These results
strengthen the view that GSDMD is a key effector of the NLRP3 inflammasome pathway.
The identification of more than 100 NLRP3 sequence variants underscores the challenges
of genotype–phenotype relationship studies for CAPS [30]. In efforts to fill this gap, several
preclinical CAPS-relevant models were developed [25–28]. They included knockin mice,
which harbored a D301N NLRP3 mutation, the mouse ortholog of the human D303N muta-
tion found in NOMID patients [25]. Mating of Nlrp3fl(D301N)/+ mice with lysozyme M-Cre−/+
(LysM-Cre−/+) mice yielded control and Nlrp3fl(D301N)/+;LysM-Cre−/+ mice, in which the auto-
somal dominant mutation in Nlrp3 was induced in myeloid cells; these mice are referred to as
NOMID mice. We previously reported that the phenotype of NOMID mice with myeloid-
restricted activation of NLRP3, which included systemic inflammation and skeletal anomalies,
resembled that of mice broadly expressing the mutated protein [25, 31, 32]. This mouse model
provided the opportunity to determine the impact of GSDMD deficiency in the pathogenesis
of NOMID. Consistently, GSDMD cleavage in WT BMMs required priming and secondary
signals triggered by LPS and nigericin, respectively (Fig 1D). By contrast, GSDMD proteolysis
in NOMID BMMs was induced by LPS alone though the response was maximal in the pres-
ence of the ionophore. Likewise, secretion of IL-1β and LDH by WT cells necessitated the
combined actions of LPS and nigericin, whereas these responses were significantly induced by
the endotoxin alone in NOMID cells (Fig 1E and 1F; and S1 Data). Notably, secretion of IL-1β
and LDH was abolished in cells lacking GSDMD. Thus, mature IL-1β is constitutively pro-
duced in NOMID cells, but its release requires GSDMD.
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Fig 1. GSDMD cleavage correlates with IL-1β secretion and pyroptosis. BMMs were isolated from WT, Gsdmd−/−, Nlrp3−/−, Casp1−/−,
Casp11−/−, NOMID, or NOMID;Gsdmd−/− mice and were expanded in vitro in the presence of M-CSF-containing media. BMMs were
primed with LPS for 3 hours and treated with nigericin for 30 minutes. (A, D) Western blot analysis of cell lysates. (B, E) IL-1β levels in
conditioned media. (C, F) Percent of LDH release in conditioned media. Data are mean ± SEM from experimental triplicates and are
representative of at least three independent experiments. The numerical values underlying Fig 1B, 1C, 1E and 1F can be found in S1 Data.
����P< 0.0001. BMM, bone marrow–derived macrophage; Casp, caspase; GSDMD, gasdermin D; IL-1β, interleukin-1β; LDH, lactate
dehydrogenase; LPS, lipopolysaccharide; M-CSF, macrophage colony-stimulating factor; NOMID, neonatal-onset multisystem
inflammatory disease; WT, wild-type.
https://doi.org/10.1371/journal.pbio.3000047.g001
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Anomalies in NOMID mice are prevented by deletion of Gsdmd
NOMID mice are runted, and they usually die by 2 to 3 weeks of age [25, 31], whereas Gsdmd
null mice are apparently normal [16]. Consistent with these reports, NOMID pups were indis-
tinguishable from WT and Gsdmd null littermates at birth but exhibited growth retardation
and significantly lower body weight by 12 days of age (Fig 2A and 2B; S1A Fig and S1 Data).
Additional macroscopic aberrations in NOMID mice included the presence of skin lesions
(Fig 2A) and splenomegaly (Fig 2C and 2D; S1 Data). Skin and spleen abnormalities and the
small body size phenotype of NOMID were all normalized in mutant mice lacking GSDMD
(Fig 2A–2D). Growth delay, systemic inflammation, perinatal lethality, and spleen and skin
abnormalities have been reported for other models of CAPS [26, 27, 29]. Deletion of Il-1
Fig 2. GSDMD deficiency prevents the stunt and splenomegaly phenotype of NOMID mice. (A) Representative pictures of mice from each
genotype. White arrow indicates skin lesions. (B) Body weight of mice. (C) Representative pictures of the spleen of mice from each genotype.
(D) Percent of spleen weight. Data are mean ± SEM from WT mice (3 males and 1 female), NOMID mice (3 males and 2 females), NOMID;
Gsdmd−/− mice (2 males and 1 female), and Gsdmd−/− mice (3 males and 4 females). The weight of 1 male NOMID;Gsdmd−/− mouse who was
left to age is 5 g on day 12, 5.4 g on day 21, and 20.7 g on day 66. The numerical values underlying Fig 2B and 2D can be found in S1 Data.
���P< 0.0005; ����P< 0.0001. GSDMD, gasdermin D; NOMID, neonatal-onset multisystem inflammatory disease; WT, wild-type.
https://doi.org/10.1371/journal.pbio.3000047.g002
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receptor completely abolished these outcomes in NOMID mice but not in FCAS and MWS
mice [8, 29], findings that are consistent with the view that, in contrast to humans, FCAS and
MWS are unexpectedly more severe than NOMID in mice. The release of not only IL-1β and
IL-18 but also other pro-inflammatory factors during pyroptosis may be responsible for the
persistent residual inflammatory responses in FCAS and MWS models. Thus, it will be infor-
mative to determine the effects of GSDMD deficiency on disease progression in other preclini-
cal models of CAPS.
While we were wrapping up this work, a report indicated that lack of GSDMD in mice pre-
vented the onset and progression of Familial Mediterranean Fever, a disease in which aberrant
pyrin inflammasome activities caused IL-1β oversecretion and pyroptosis [33]. Deficiency in
GSDMD also protected mice against endotoxic shock, consistent with activation of this protein by
intracellular LPS [14, 16]. A recent paper suggested an interplay between caspase-8 and caspase-
11-GSDMD axis in the execution of endotoxic shock [34]. Collectively, these findings indicate
that inactivation of GSDMD arrests pathogenic signals induced by various inflammasomes.
Systemic inflammation and organ damage in NOMID mice are prevented
by ablation of Gsdmd
IL-1β propagates inflammation through various mechanisms, including perturbation of che-
mokine and cytokine signaling networks, responses that lead to the expansion and recruitment
of neutrophils to several organs. This cytokine also promotes anemia owing to its negative
effects on erythroid progenitors and erythropoietin signaling as well as alteration of the expres-
sion of ferritin and ferroportin [35–38]. Accordingly, NOMID mice produced higher levels of
IL-1β in bone marrow compared to WT counterparts (Fig 3A and S1 Data), a response that
correlated with excessive GSDMD processing in vivo in bone marrow, though the cleaved frag-
ment was barely detected in this compartment (S1B Fig). This observation was not unexpected
considering that excessive generation of GSDMD-N caused cytolysis; as a result, the cleaved
fragment may have been lost during the sampling process. NOMID mice also exhibited
peripheral leukocytosis (Fig 3B and S1 Data) driven by neutrophilia (Fig 3C and S1 Data) and
anemia (Fig 3D; S1C Fig and S1 Data), as we previously reported [25, 32]. The identity of mye-
loid cell subpopulations, which are prone to pyroptosis and propagate inflammation, in this
model is unknown, a knowledge gap that future studies should address. In any case, while
Gsdmd ablation had no effect on the number of blood cells compared to WT mice, it abrogated
or attenuated the onset of leukocytosis and anemia in NOMID mice (Fig 3A–3D). Accord-
ingly, the bone marrow compartment of NOMID mice contained abnormally high levels of
Gr1+/CD11b+ cells and low levels of Ter119+ cells (Fig 3E and 3F; S1 Data), responses that
were normalized upon Gsdmd deletion.
Histological analyses showed massive neutrophilic infiltration in the liver, dermal and
hypodermal layers of the skin, and the spleen of NOMID mice compared to WT or Gsdmd−/−
counterparts (Fig 4). Inflammation in the spleen was characterized by disorganized structures
of white and red pulps. Because skeletal complications—including low bone mass—are hall-
marks of NOMID, we investigated these outcomes in NOMID mice. Histological examina-
tions of skeletal elements showed disorganized columns of chondrocytes with profoundly
altered morphology. The epiphysis was hypocellular (Fig 4), a phenotype that was previously
reported to be caused by massive chondrocyte death [25, 32] and reminiscent of the human
disease [39]. The number of osteoclasts, cells responsible for bone resorption, was markedly
increased in NOMID mice relative to control mice. Remarkably, all organs that were analyzed
in NOMID;Gsdmd−/− mice were all spared from inflammation-induced damage (Fig 4). Thus,
deletion of GSDMD abolishes inflammatory responses and organ demise in NOMID mice.
GSDMD deficiency prevents the onset of NOMID
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Fig 3. GSDMD deficiency prevents the onset of systemic inflammation in NOMID mice. (A) IL-1β levels in mouse bone marrow
supernatants. (B) WBC counts. (C) Neutrophils. (D) RBCs. (E) Flow cytometry analysis of bone marrow cells stained with antibodies
against CD11b, Gr-1, or Ter119. (F) Quantitative data from flow cytometry dot plots shown in panel E. Data are mean ± SEM. Three-
week-old mice were used for the studies. WT mice (panel A: 2 males and 1 female; panel B and C: 3 males and 2 females; panel D: 5 males
and 4 females; panel F: 2 males and 1 female for CD11b+/Gr-1+, and 3 males and 1 female for Ter119+). NOMID mice (panel A: 2 males
GSDMD deficiency prevents the onset of NOMID
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Blockade of IL-1 activity has been the main strategy for neutralizing pathogenic signals
induced by this cytokine in CAPS and other autoinflammatory disorders. However, these
drugs have shortcomings, including high cost and the requirement for parenteral administra-
tion. Thus, there is still a medical need for the development of safe and affordable drugs for the
treatment of autoinflammatory diseases. Breakthrough research demonstrating that GSDMD-
mediated pyroptosis releases cytoplasmic contents, including IL-1β and IL-18, offers a novel
node for therapeutic intervention. Stemming from its mechanisms of action, blockade of
and 1 female; panel B and C: 4 males and 3 females; panel D: 4 males and 3 females; panel F: 2 males and 1 female). NOMID;Gsdmd−/−
mice (panel A: 2 males and 1 female; panel B–F: 2 males and 1 female); Gsdmd−/− mice: (panel A: 2 males and 1 female; panel B and C: 3
males and 3 females; panel D: 4 males and 4 females; panel F: 3 males and 1 female). The numerical values underlying Fig 3A, 3B, 3C, 3D
and 3F can be found in S1 Data. �P< 0.05; ��P< 0.005; ���P< 0.0005; ����P< 0.0001. GSDMD, gasdermin D; IL-1β, interleukin-1β;
NOMID, neonatal-onset multisystem inflammatory disease; RBC, red blood cell; WBC, white blood cell; WT, wild-type.
https://doi.org/10.1371/journal.pbio.3000047.g003
Fig 4. GSDMD deficiency prevents damage to multiple tissues in NOMID mice. Representative images of liver,
skin, and spleen from 3-week-old WT mice (3 males and 1 female), NOMID mice (3 males and 1 female), NOMID;
Gsdmd−/− mice (2 males) and Gsdmd−/− mice (3 males and 1 female) stained with HE. Femurs were stained for TRAP
activity. Red circle indicates area of hypocellularity in the epiphysis. Osteoclasts are stained in red. Scale bar: 200 μm.
GSDMD, gasdermin D; HE, hematoxylin–eosin; NOMID, neonatal-onset multisystem inflammatory disease; TRAP,
tartrate-resistant acid phosphatase; WT, wild-type.
https://doi.org/10.1371/journal.pbio.3000047.g004
GSDMD deficiency prevents the onset of NOMID
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GSDMD and subsequently pyroptosis should, in theory, provide superior efficacy compared
with targeted blockade of IL-1β. The compelling evidence indicating that inactivation of
GSDMD blocks inflammatory responses induced by the NLRP3 inflammasome lends support
to discovery efforts aimed at identifying selective inhibitors of GSDMD actions.
Materials and methods
Ethics statement
All procedures were approved by the Institutional Animal Care and Use Committee (IACUC)
of Washington University School of Medicine in St. Louis, Missouri. All experiments were per-
formed in accordance with the relevant guidelines and regulations described in the IACUC-
approved protocol number 20160245.
Mice
Gsdmd−/− mice [16] were kindly provided by Dr. V. M. Dixit (Genentech, South San Fran-
cisco, CA). Nlrp3−/−, Casp1−/−, and Nlrp3fl(D301N)/+ mice and lysozyme M (LysM)-Cre mice
have previously been described [25, 31, 40, 41]. Casp11−/− mice were purchased from The Jack-
son Laboratory. All mice were on the C57BL6J background, and mouse genotyping was per-
formed by PCR.
Peripheral blood and bone marrow analyses
Complete blood counts were performed by the Washington University School of Medicine
DCM Diagnostic Laboratory as previously described [31]. Bone marrow cells were flushed out
as previously described, and photographed [31].
Cell cultures
BMMs were obtained by culturing mouse bone marrow cells in culture media containing a
1:25 dilution of supernatant from the fibroblastic cell line CMG 14–12 as a source of M-CSF, a
mitogenic factor for BMMs, for approximately 5 days in a 10-cm dish following the procedures
that we published [42]. Nonadherent cells were removed by vigorous washes with PBS, and
adherent BMMs were detached with trypsin-EDTA and were cultured in culture media con-
taining a 1:50 dilution of CMG at 4 × 104/well in a 96-wells plate (for the analysis of IL-1β and
LDH) or 1.2 × 106/well in a 6-wells plate (for Western blot analysis).
Western blot
BMMs were treated with 100 ng/mL LPS for 3 hours, then with 15 μM nigericin for 30 min-
utes. Extracts from BMMs or bone marrow cells were prepared by lysing cells or cell pellets,
respectively, with RIPA buffer (50 mM Tris, 150 mM NaCl, 1 mM EDTA, 0.5% NaDOAc,
0.1% SDS, and 1.0% NP-40) plus phosphatase inhibitors and Complete Protease Inhibitor
Cocktail (Roche, Brighton, MA). Protein concentrations were determined by the Bio-Rad
method, and equal amounts of proteins were subjected to SDS-PAGE gels (12%). Proteins
were transferred onto nitrocellulose membranes and incubated with GSDMD antibody
(1:1,000, ab209845, Abcam, Cambridge, MA) or β-actin (1:5,000, sc-47778, Santa Cruz Bio-
technology, Dallas, Texas) overnight at 4˚C, followed by a 1-hour incubation with secondary
goat anti-mouse IgG (1:5,000, A21058, Thermo Fisher Scientific, Grand Island, NY) or goat
anti-rabbit IgG (1:5,000, A21109, Thermo Fisher Scientific), respectively. The results were
visualized using Li-Cor Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln,
Nebraska).
GSDMD deficiency prevents the onset of NOMID
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Flow cytometry
Mouse bone marrow cells were flushed from femur and tibia. For flow cytometry analysis of
the leukocytes, red blood cells (RBCs) were depleted with RBC lysis buffer (Roche, Brighton,
MA). Cells (0.5–1 × 106) were incubated with Fc block (anti-mouse CD16/32, BioLegend, San
Diego, CA) to block nonspecific Fc binding, stained with isotype control or APC-anti-mouse
Ter119 (BioLegend, San Diego, CA), FITC-anti-mouse CD11b (eBioscience, Grand Island,
NY), and PE-anti-mouse Ly-6G/Ly-6C (Gr1) antibody (BioLegend, San Diego, CA) according
to the supplier’s instructions. Flow cytometry was performed using BD LSRFortessa or BD
FACSCanto II Flow Cytometer system, followed by analysis with FlowJo software (Tree Star,
Ashland, Oregon).
Histology
All tissues were harvested and fixed in 10% formalin. Long bones were decalcified in 14% (w/
v) EDTA for 5 days at room temperature. All tissues were embedded in paraffin, sectioned at
5 μm thickness, and mounted on glass slides. Sections were stained with hematoxylin–eosin
(HE) or TRAP as previously described [42].
Cytotoxicity assay and IL-1β ELISA
BMMs were treated with 100 ng/mL LPS for 3 hours, then with 15 μM nigericin for 30
minutes.
Cell death was assessed by the release of LDH using LDH Cytotoxicity Detection Kit
(TaKaRa, Mountain View, CA). IL-1β levels in conditioned media were measured by ELISA
(eBiosciences, Grand Island, NY). For IL-1β measurements in bone marrow, flushed bone
marrow was centrifuged, and the supernatants were collected as described previously [42]. IL-
1β levels were quantified using the eBioscience ELISA kit.
Statistical analysis
Statistical analysis was performed using one-way ANOVA with Tukey’s multiple comparisons
test or two-way ANOVA with Tukey’s multiple comparisons test in GraphPad Prism 7.
Supporting information
S1 Fig. GSDMD deficiency prevents the stunt and anemic phenotype of NOMID mice. (A)
Representative pictures of mice from each genotype from a cohort of mice different from the one
shown in Fig 2. Red arrows indicate skin lesions. Pictures of 12-day-old WT mice (2 males);
NOMID mice (1 male and 1 female), NOMID;Gsdmd−/− mice (2 males), and Gsdmd−/− mice (1
male and 1 female). (B) Western blot analysis of bone marrow cell extracts. (C) Pictures of pellets
of bone marrow cells isolated from 3-week-old WT, NOMID, NOMID;Gsdmd−/−, or Gsdmd−/−
mice.
(PDF)
S1 Data. Data for Fig 1B, 1C, 1E and 1F, Fig 2B and 2D, and Fig 3A, 3B, 3C, 3D and 3F.
(XLSX)
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